The therapeutic community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s exhibiting significant promise in clinical trials for addressing obesity. Unlike some existing weight loss solutions, retatrutide appears to deliver a more substantial decreas